Smart Pc Care Serial Key
Iberio Ralda
Vanco Child Care serves a wide variety of child care, Pre-K-12 education, school districts, and community organizations with its comprehensive platform. Smartcare technology connects hundreds of thousands of parents to preschools, early childhood learning programs, before and after care programs, daycares, enrichment programs, and more. Every interaction tells a story of the impact our clients are making in the communities they serve.
Smartcare acquires Childcare Manager, one of the most respected brands in the childcare management software industry, gaining team members with invaluable experience and a customer base with years of proven success.
Smartcare acquires Preschool2Me, a leading provider of lesson planning, curriculum and assessments as well as after school care solutions. The new features allow us to move closer to our vision as an all-inclusive platform for childcare providers.
Smartcare is acquired by Vanco, a leading technology and payment solutions provider for the education, faith-based, and nonprofit sectors. Both our teams and our technology combine to deliver even better features and exceptional customer service to child care providers.
Smartcare, Preschool2Me, and Childcare Manager officially become Vanco Child Care, a holistic suite of tools that combines the best of the old brands into a new, comprehensive childcare management platform.
i need to know what counts as a care mistake in the smart?! its still kinda new so i couldnt really find information about it. in my first gen i got milktchi- female perfect care tama and in my second i got her again even though i ((tried)) to neglect her during her baby/ child/ teens years! she ended up as kyupitchi so i thought i was on a good track (though i understand that the stages before adults are based off fondness and not care mistakes)
Recently discharged patients often face a risk of readmission following their hospitalization. For some patients, follow up care can be difficult to coordinate, or there may be confusion about medication management.
Smartcare Paramedics undergo specialized training in direct in-home patient care and communication and have a minimum of 5 years of field experience with at least 3 years in a 911 emergency environment.
Smart Care offers holistic healthcare for proactively shaping individual health and improving the quality of life of the population. Regionally independent and close to home, the approach is based on hybrid healthcare, combining familiar traditional care with flexible availability of medical providers in terms of time and personnel, as well as modern digital and tele-medical options. The SmartCare platform is your trusted personal health expert, available anytime, anywhere, regularly collecting health data, ensuring availability of medical expertise and documentation of health data.
The SmartCARE project aims to develop an EU-level Cancer Survivor Smart Card to improve the quality of life and health status of cancer survivors. The mobile and web app will provide new support to under-met needs related to the medical and psycho-social aspects of cancer survivorship. The project will deliver an interoperable smart card solution that is readily available to survivors and their families, with the patient voice in mind. This will involve working with different categories of survivors and their caregivers to shape the specifications of the app.
In the advanced education clinics, residents (dentists who are seeking further specialized training) provide patient care under the close supervision of school faculty members. Dental care is not provided free of charge, but fees in the advanced education clinics are heavily reduced from the cost of treatment in private dental care.
Survival and quality of life for patients affected by spinal muscular atrophy (SMA) are thought to have improved over the last decade due to changes in care. In addition, targeted treatments for SMA have been developed based on a better understanding of the molecular pathology. In 2016 and 2017, nusinersen was the first drug to be approved for treatment of all types of SMA in the United States and in Europe based on well-controlled clinical trials in a small subgroup of pediatric SMA patients. Systems are required to monitor treated and untreated SMA patients in a real-life environment to optimize treatment and care, and to provide outcome data to regulators, payers, and the SMA community.
Within SMArtCARE, we conduct a prospective, multicenter non-randomized registration and outcome study. SMArtCARE collects longitudinal data on all available SMA patients independent of their actual treatment regime as disease-specific SMA registry. For this purpose, we provide an online platform for SMA patients seen by health-care providers in Germany, Austria and Switzerland. All data are collected during routine patient visits. Items for data collection are aligned with the international consensus for SMA registries. Data analysis is carried out independent of commercial partners.
A prospective monitoring of all SMA patients will lead to a better understanding of the natural history of SMA and the influence of drug treatment. This is crucial to improve the care of SMA patients. Further, we will establish a network for neuromuscular centers to share experience with SMA patients and to promote research projects on SMA.
The natural history of SMA has changed over the last decade due to improvements in care. For example, with non-invasive ventilator support and enteral feeding, survival of the critically ill infants with SMA type 1 has increased [2, 3]. A revised consensus statement for standards of care in SMA has been published recently [4, 5], but nonetheless, there is high variability in the care for SMA patients.
Targeted treatments for SMA have been developed in preclinical and clinical studies. Among these, several drugs have already reached clinical trials of phase I-III [6,7,8]. Nusinersen was the first drug to be approved for treatment of all types of SMA based on well-controlled clinical trial data of a small subgroup of pediatric SMA patients [9, 10]. Prior to approval in Europe, nusinersen was provided to patients with SMA type 1 within an Expanded Access Program (EAP). Data of all available patients were systematically collected in 7 neuromuscular centers in Germany so that we could evaluate the response to treatment with nusinersen in a broader spectrum of SMA type 1 patients [11]. But still, considering current age and disease stage, most SMA patients are outside the population that has been studied in randomized controlled trials. Thus, there is a strong need to monitor all treated and untreated SMA patients in a real-life environment to optimize treatment and care.
We conduct a prospective, multi-center non-randomized registration and outcome study in Germany, Austria and Switzerland. For this purpose, we provide an online platform for SMA patients seen by health-care providers. This data collection is conducted in addition to the existing SMA patient registry in Germany (www.sma-register.de).
All neuromuscular centers that care for patients with SMA are invited to participate in this study. Neuromuscular centers that provide treatment with nusinersen were identified by the German Society for people with Muscular Diseases (Deutsche Gesellschaft für Muskel-kranke (DGM) e.V.). To date, already 50 neuromuscular centers confirmed their participation in the SMArtCARE data collection so that we expect data of approximately 1,000 SMA patients within the first year of the study. The participating centers are displayed in Fig. 1.
Inclusion criteria for patients are defined as genetically confirmed 5q-SMA and that the patient or the caregivers have given a written informed consent. To avoid selection bias, physicians are asked to include all patients fulfilling the inclusion criteria in a consecutive way independent on their treatment regime.
For the SMArtCARE data collection, an electronic data capture (EDC) system is used. This system is a web-based data entry system that is developed by OpenApp LTD and hosted within the IT infrastructure of the University Medical Center Freiburg. For data entry, different, standardized e-forms are provided. The aim of the IT platform is to support care of SMA patients with a standardized anamnesis questionnaire in accordance with the published standards of care [4, 5]. To facilitate the management and care of SMA patients, specific features are implemented in the IT system. Based on the age of the patient and the previously entered data, the respective selection of e-forms is proposed when planning a new patient visit. The next visit is scheduled dependent on the current treatment of the patient. Reports can be printed for every patient visit to reduce the documentation effort. For each patient, a diagram is displayed to give an overview of changes in motor or respiratory function, adverse events or drug treatment for the investigator. Further, to report drug-related adverse events, the system will provide a printable, standardized form that can be transferred to the respective authorities. If sub-studies are conducted using the infrastructure of SMArtCARE, specific e-forms can be implemented in the IT system and, if required, these additional e-forms can be used only in a sub-group of patients.
The evaluation of real-life outcome data in a broad spectrum of SMA patients will lead to a better understanding of the natural history and the influence of drug treatment. This is crucial to revise and implement standards of care for these patients. The IT system of the SMArtCARE database will help to implement recommendations for the care of SMA patients according to the international consensus for standards of care [4, 5]. To enable an international collaboration and data sharing, data items are standardized and aligned with the international consensus of SMA registries. At last, we strive to establish a network for neuromuscular centers in Germany, Austria and Switzerland to share experience with SMA patients and to promote research projects using the infrastructure of the SMArtCARE database.
582128177f